1.1
Adalimumab is recommended as an option for treating plaque psoriasis in children and young people aged 4 years or older, only if the disease:
-
is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
-
has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.